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and remain at risk for active tuberculosis. Marcel A Behr and colleagues argue that most of these
people are no longer infected
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Key messages
Two billion people worldwide are thought to be asymptomatically (latently)
infected with Mycobacterium tuberculosis and at risk of developing active
tuberculosis (TB)
The prevalence of latent TB infection is inferred from tests that detect
immunoreactivity to mycobacterial antigens rather than live bacteria and
from mathematical modelling
Longitudinal studies and clinical trials show that this TB immunoreactivity
can persist after curative treatment
Most people with TB immunoreactivity do not develop active TB upon
immunosuppression, suggesting that they have cleared their infection
while retaining immunological memory to it
TB immunoreactivity cannot distinguish cleared from persistent infection,
emphasising the urgent need for tests that can identify people with
asymptomatic infections
A critical component of the World Health Organization’s End
TB strategy is the prevention of active tuberculosis (TB) by
treating people with latent TB infection.1 2 This requires
knowledge of who is latently or asymptomatically infected with
Mycobacterium tuberculosis. As there are no direct tests for
asymptomatic infection, it is inferred from the presence of TB
immunoreactivity, determined by either a tuberculin skin test
(TST) or an interferon gamma release assay (IGRA). The use
of immunoreactivity as a proxy for infection is based on the
assumption that those testing positive harbour live bacteria,
which might be quiescent now but can spring to activity to cause
disease later, especially if the host becomes
immunocompromised.2 3
Is this assumption valid? Knowing this would be useful for
several interested parties—public health officials, TB
researchers, people showing TB immunoreactivity, and doctors.
We tested the assumption that TB immunoreactivity equals
persistent infection by analysing the natural history of TB
immunoreactivity in people given preventive treatment and of
active TB in immunoreactive people with various forms of
severe immunosuppression.
Immunoreactivity does not reflect
continued infection
For TB immunoreactivity to be a reliable proxy for persistent
TB infection, it must track faithfully with infection. This means
that people whose infection is cured should become
non-reactive. Multiple studies show that this is not the case.
The large US isoniazid chemoprophylaxis trial conducted
between 1956 and 1966 showed that treatment of people with
TB immunoreactivity (TST results ≥10 mm) for one year
lowered the incidence of active TB by 60-70% over the next
nine years (fig 1A).4 Yet the treated people remained positive
on TST up to nine years after treatment (fig 1B), showing that
TB immunoreactivity can outlast elimination of infection by at
least nine years.
This finding was validated by two studies that provided
mechanistic insights. Among hospital employees, Atuk and
Hunt showed that patients who had positive results on TSTs for
more than a year before treatment remained so after treatment,
whereas 50% of those who had been positive for less than a
year became negative or had smaller TST induration size (fig
1C).5 Houk and colleagues’ study of US navy sailors treated
with isoniazid for TB infection provided more granularity.6 All
who were immunoreactive for more than a year before treatment
remained so after treatment; among the remainder, those who
were immunoreactive the longest were most likely to remain
so after isoniazid treatment (fig 1D). These findings are
consistent with the development of a lasting immunological
memory that becomes more robust with longer exposure to
antigen. Finally, the finding that TB immunoreactivity outlasts
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infection holds in the context of active TB—people remain
immunoreactive after completing treatment with highly effective
multidrug regimens.7 8
So TB immunoreactivity is not a marker for the presence of
continued TB infection. Rather it serves as a sign of having
been infected with TB but does not reflect the
outcome—bacterial clearance versus persistence.
Immunosuppression and risk of TB
Immunosuppression—through HIV infection or medical
intervention (tumour necrosis factor (TNF) inhibition, solid
organ transplantation, and haematopoietic stem cell
transplantation)—is associated with an increased risk of active
TB in multiple studies. We used these studies to infer the
frequency of persistent infection in people showing TB
immunoreactivity (see supplementary table 1 and supplementary
methods for details on data sources and analysis).
TNF inhibition
TNF is known to be a potent determinant of resistance to TB
in animal disease models.9 10 The increased risk of TB in humans
receiving the anti-TNF antibody infliximab was shown first in
2001 in a large US patient cohort11 and then in three subsequent
studies in the US, France, and Spain (supplementary table 1 and
supplementary methods).12-14 In these studies, performed before
isoniazid prophylaxis was routinely given to TB immunoreactive
patients, 0.6-4.9% of people with positive TSTs developed TB;
the rest remained free of TB over the next 1.5 to 3 years (fig
2A).11-14 Because the majority of cases occurred early after
starting anti-TNF treatment (median time of three months) (fig
2B), TB probably resulted from pre-existing remote infection
rather than from newly acquired infection. Together, these
analyses show that >95% of people with positive TSTs do not
have quiescent bacteria that can be roused by TNF suppression.
HIV
Cell mediated immunity, especially that mediated by CD4+ T
lymphocytes, is another critical defence against TB, as shown
by the increased rates of TB in people with HIV. Two studies
on TB in patients with HIV were done at a time when preventive
TB treatment was not routinely given to patients with HIV who
were TB immunoreactive. Both studies used bacterial
genotyping to distinguish newly acquired from pre-existing
remote TB infection, showing that 88.7% and 97.5% of people
with positive TSTs remained free of TB from their remote
infection over a five year period (fig 3A).15 16
Solid organ transplantation
Long term medical suppression of cell mediated immunity is
the cornerstone of preventing rejection after allogeneic organ
transplantation. Three studies of solid organ transplant recipients
who did not receive isoniazid prophylaxis were done in Spain,
Turkey, and the US. Most of these patients remained free of TB
(88.7-95.6%) over observation periods of up to 2.5 years (fig
3B).17-19 The maximum reported rate of TB in people with
positive TSTs was 11.3%. TB occurred later in the transplant
population than in the population receiving TNF inhibition, with
a median of six months for a cohort comprising mostly non-renal
transplants (67%) and 12 months for renal transplants (from a
different study of exclusively renal transplants) (figs 3C and
3D). This could reflect a later temporal role for cell mediated
immunity in the control of TB. The shorter time to TB in
non-renal transplant recipients might reflect the higher degree
of immunosuppression used. Some of the later cases might have
been from newly acquired infection after the transplant, in which
case the estimated risk attributable to remote infection would
be even lower.
Haematopoietic stem cell transplantation
Haematopoietic stem cell transplantation results in the most
profound and rapid immunosuppression affecting both innate
and adaptive arms of immunity; this is the most likely form of
immunosuppression to cause any quiescent M tuberculosis to
become active. We identified four cohorts of TB
immunoreactive people in India, South Korea, Taiwan, and the
US who underwent haematopoietic stem cell transplantation
without receiving isoniazid prophylaxis.20-23 The proportion of
these cohorts that developed TB was less than 10% (fig 4A). In
the US cohort, none of 29 participants with TB immunoreactivity
developed TB after a total of 89 person years of observation.
The three other studies were performed in countries with
intermediate to high TB burden, yet only 7-10% of people
developed TB. The median times to TB development after
transplantation were 258, 368, and 445 days for the Indian,
South Korean, and Taiwanese studies (fig 4B), respectively,
indicating that some of these cases might have been due to new
infection rather than activation of their remote infection.
BCG and false positives
BCG vaccination can result in false positive results on TSTs in
those vaccinated when older than 1 year of age.24 This could
have falsely inflated the number of people estimated to be TB
immunoreactive in the studies that we analysed. If so, the
proportion of TB immunoreactive people who developed TB
associated with immunosuppression would have been higher
than our estimates. To ensure that this was not the case, for each
study we determined the use of BCG vaccine in the appropriate
country and whether the more specific IGRA tests25 were used
to determine TB immunoreactivity. We concluded that our
estimates of TB immunoreactivity were not falsely high because
of BCG vaccination (see supplementary table 2).
Summary and implications
Whether infected people can clear M tuberculosis has consumed
TB researchers for over a century, yet multiple approaches have
failed to yield a definitive answer. Our analysis of
epidemiological experiments suggests the answer: between 1%
and 11% of people with TB immunoreactivity continue to
harbour viable bacteria capable of causing disease. In the
remainder, the organisms are either dead or have lost their
pathogenic potential. The latter scenario would be extraordinary.
It would differ from a multitude of other quiescent infections
where immunosuppression is recognised to cause a reactivation
or exacerbation of infection.26 Cytomegalovirus, herpes simplex
virus, herpes zoster virus, the protozoan Toxoplasma gondii,
and the fungus Cryptococcus neoformans are known to produce
full blown devastating infections from a long term latent
infection.
This analysis highlights that the currently available tests for
latent TB infection detect only TB reactivity—that is,
immunological memory and recall responses. So they would
not be expected to distinguish between long lived memory that
persists after elimination of M tuberculosis antigens and T cell
responses maintained by repeated antigen stimulation from
chronic infection. Many infectious diseases (including hepatitis
A, B, and C) as well as immunisation with attenuated or subunit
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vaccines generate memory responses (antibody, T cell, or both)
that do not reflect pathogen persistence.
We hope that our analysis will stimulate further discussion about
the research and biological paradigms of TB. If infection is
forever, researchers will aim to study host tolerance. If infection
can be cleared, researchers will try to understand the
mechanisms of pathogen elimination.
Our findings indicate that the tests used in biomarker and
immunological studies of persistent infection (TST and
IGRA)27 28 might have two major confounders: the control
participants who do not develop TB might be a heterogeneous
mix of currently and previously infected people; and efforts to
find a profile that predicts increased risk of disease might be
confounded by the control group (TST positive) being at reduced
risk of TB, as has been shown in multiple observational studies.29
Notwithstanding the challenges of evaluating new biomarkers,
the importance of identifying the proportion of people with
persistent infection and distinguishing them from those with
immunological memory of past infection cannot be overstated.
A test that could identify the 10% who are infected should
reduce the cost and morbidity of treatment 10-fold while
maintaining the effectiveness of the intervention. Until we have
such a test, our analysis does not affect clinical guidelines for
the current methods of detection and preventive treatment of
TB infection; rather, our analysis reinforces that a key aspect
of TB prevention strategies is to target the people at highest
risk, who stand to benefit the most from intervention.
Finally, if 90% of people with TB immunoreactivity do not
develop active TB when challenged with TNF neutralising
antibodies, HIV, anti-rejection drugs or haematopoietic stem
cell transplantation, it is unlikely that a central assumption in
the global burden of TB infection has been fulfilled. Current
estimates indicate that 25-30% of the world’s population are
infected with TB and at risk of TB disease based on the explicit
premise that infection is life long.30 If people are capable of
clearing infection, then estimates of the global prevalence of
infection, which are based on the cumulative incidence of new
infections, need to be revisited and revised.
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Fig 1 TB immunoreactivity reversion over time. A) Efficacy of one year of isoniazid prophylaxis (n=9382) versus placebo
(n=9140) over a 10 year observation period, including the year of treatment, for residents of US mental institutions.4
Isoniazid treatment reduced TB disease by 62% over the observation period. B) TB immunoreactivity over a 10 year
observation period for residents of Milledgeville mental institution participating in a placebo controlled (n=697) trial
of isoniazid treatment (n=686) to prevent TB infection, all of whom were TB immunoreactive at enrolment.4 C) TB
immunoreactivity for University of Virginia Hospital workers with known duration of TST positivity (<1 year (n=20) and
>1 year (n=17)) before isoniazid treatment for one year.5 D) TB immunoreactivity for US navy sailors with known
duration of TST positivity (1.5-3 months (n=45), 6 months (n=98), 12 months (n=36), and >12 months (n=24)) before
isoniazid treatment for one year.6 TST=tuberculin skin test.
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Fig 2 Percentage of likely or known TB immunoreactive patients who developed TB after infliximab treatment and the
kinetics of TB development in these patients. A) Percentage of patients receiving infliximab who were free of TB after
infliximab treatment, where columns A, B, C, and D are based on data from Gomez-Reino et al (n=1578),13 Baldin et
al (n=1154),12 Keane et al (n=2931),11 and Wolfe et al (n=6460).14 B) The cumulative frequency of TB development
in infliximab treated patients versus the time to develop TB after starting infliximab (n=76) from Keane et al,
Gomez-Reino et al, and Wolfe et al.11 13 14 The median, average, and 75th centile time to develop TB after initiation of
infliximab were 3, 4.5, and 5.6 months, respectively. Error bars indicate 95% confidence intervals.
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Fig 3 Percentage of patients with likely or known TB immunoreactivity who did not develop TB with immunosuppression
caused by HIV/AIDS or solid organ transplantation. A) Patients with HIV/AIDS. Data from Moss et al (A) (n=35)15 and
Horsburgh et al (B) (n=106),16 which used molecular methods to distinguish disease probably due to remote versus
new infection. Only disease due to remote TB infection is shown, in those who had not received full courses of isoniazid
preventive therapy. The observation periods were 2-5 years. B) After solid organ transplantation. Columns A, B, and
C show data from Atasever et al (n=443),17 Klote et al (n=15 870),18 and Torre-Cisneros et al (n=4388).19 C) Kinetics
of TB development after solid organ transplantation (n=21).19 The median, mean, and 75th centile times were 6.0,
5.8, and 8.0 months after transplant, respectively. D) kinetics of TB development after renal transplantation (n=66).18
The median, mean, and 75th centile times were 12.0, 13.6 and 21 months after transplant, respectively. Error bars
indicate 95% confidence intervals.
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Fig 4 TB in patients undergoing haematopoietic stem cell transplantation. A) Proportion of people with likely TB reactivity
who did not develop TB after haematopoietic stem cell transplantation. Columns A, B, C, and D data are taken from
Fan et al (n=240),20 Cheng et al (n=29),21 Lee et al (n=550),22 and Agarwal et al (n=175),23 respectively. B) kinetics of
TB development in 39 patients who developed TB over the 10 year observation period.20 The median, average, and
75th centile incubation times are 1.6, 1.8, and 2.4 years, respectively. Redrawn from Fan et al. Error bars indicate
95% confidence intervals.
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